Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hierarchical Treatment for Suspected CAD with Somatic Symptoms
NCT02723903Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Dec 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of flupentixol + melitracen and fluoxetine in somatic symptom disorder (SSD) (4 arms), sponsored by Renji Hospital. Primary endpoint: Somatization Symptom Scale Score at 2 weeks. Status: unknown.
02
Drugs
flupentixol + melitracenfluoxetine
03
Conditions
somatic symptom disorder (SSD)
Beyond the preview
Go deeper on NCT02723903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723903.